Sumitomo Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Ehime Japan (1986)
Status: Acquired by Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial
2008
NCT00660504
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sumitomo Pharmaceuticals America | Sumitomo Pharmaceutical (Suzhou) Co., Ltd. | Sumitomo Pharma Co., Ltd. | Sumitomo Pharma (Suzhou) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Disease (Phase 4)

Essential Hypertension (Phase 4)

Gastroparesis (Phase 4)

Hypertension (Phase 4)

Hypertriglyceridemia (Phase 3)

Kidney Diseases (Phase 4)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 15